Lv41
490 积分 2022-05-30 加入
中国恶性肿瘤日间诊疗专家共识(2022 版)
3小时前
已完结
健康受试者I期临床试验不良事件分级标准专家共识
3个月前
已完结
Multifaceted Nature of DNA Polymerase θ
3个月前
已完结
PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations
6个月前
已关闭
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
7个月前
已完结
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer
7个月前
已完结
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
7个月前
已完结
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
8个月前
已完结
453 Senaparib maintenance in newly diagnosed advanced ovarian cancer: FLAMES study
8个月前
已关闭
皖公网安备34019202002308
